A detailed history of Values First Advisors, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Values First Advisors, Inc. holds 8,790 shares of ALNY stock, worth $2.13 Million. This represents 1.33% of its overall portfolio holdings.

Number of Shares
8,790
Previous 7,590 15.81%
Holding current value
$2.13 Million
Previous $1.84 Million 31.07%
% of portfolio
1.33%
Previous 1.12%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$233.81 - $287.01 $280,572 - $344,412
1,200 Added 15.81%
8,790 $2.42 Million
Q2 2024

Jul 19, 2024

SELL
$143.31 - $247.0 $21,209 - $36,556
-148 Reduced 1.91%
7,590 $1.84 Million
Q1 2024

Apr 23, 2024

BUY
$146.51 - $198.2 $110,615 - $149,641
755 Added 10.81%
7,738 $1.16 Million
Q4 2023

Jan 18, 2024

BUY
$151.41 - $196.57 $72,071 - $93,567
476 Added 7.32%
6,983 $1.34 Million
Q3 2023

Nov 08, 2023

SELL
$170.77 - $211.65 $8,538 - $10,582
-50 Reduced 0.76%
6,507 $1.15 Million
Q2 2023

Aug 02, 2023

BUY
$185.01 - $212.05 $27,011 - $30,959
146 Added 2.28%
6,557 $1.25 Million
Q1 2023

May 15, 2023

BUY
$182.66 - $235.53 $19,909 - $25,672
109 Added 1.73%
6,411 $1.28 Million
Q4 2022

Jan 20, 2023

BUY
$185.53 - $241.31 $6,493 - $8,445
35 Added 0.56%
6,302 $0
Q3 2022

Dec 02, 2022

BUY
$138.54 - $232.0 $27,846 - $46,632
201 Added 3.31%
6,267 $1.25 Million
Q2 2022

Jul 20, 2022

SELL
$120.42 - $169.29 $51,780 - $72,794
-430 Reduced 6.62%
6,066 $885,000
Q1 2022

May 03, 2022

BUY
$127.18 - $173.91 $44,131 - $60,346
347 Added 5.64%
6,496 $1.06 Million
Q4 2021

Mar 10, 2022

BUY
$159.56 - $209.29 $981,134 - $1.29 Million
6,149 New
6,149 $1.04 Million
Q3 2021

Nov 15, 2022

BUY
$169.75 - $207.73 $76,557 - $93,686
451 Added 7.43%
6,517 $1.23 Million
Q2 2021

Nov 15, 2022

SELL
$128.63 - $176.89 $16,721 - $22,995
-130 Reduced 2.02%
6,304 $1.07 Million
Q1 2021

Nov 15, 2022

BUY
$126.83 - $175.69 $46,673 - $64,653
368 Added 6.07%
6,434 $908,000
Q4 2020

Nov 15, 2022

SELL
$122.97 - $147.0 $24,471 - $29,253
-199 Reduced 3.05%
6,335 $823,000
Q3 2020

Nov 15, 2022

BUY
$121.19 - $165.49 $40,113 - $54,777
331 Added 5.34%
6,534 $951,000
Q2 2020

Nov 15, 2022

BUY
$104.21 - $156.44 $23,030 - $34,573
221 Added 3.69%
6,203 $919,000
Q1 2020

Jan 09, 2023

BUY
$93.12 - $133.99 $7,635 - $10,987
82 Added 1.31%
6,349 $691 Million
Q4 2019

Nov 15, 2022

SELL
$74.51 - $124.23 $6,258 - $10,435
-84 Reduced 1.38%
5,982 $689,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.8B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Values First Advisors, Inc. Portfolio

Follow Values First Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Values First Advisors, Inc. with notifications on news.